Advancing PCOS drug development: multi-omics discovery of key targets and repurposable compounds.

Polycystic ovary syndrome (PCOS) affects millions of women of reproductive age, causing hormonal imbalances, irregular periods, and fertility challenges. Despite how common it is, treatment options remain limited and often don't address the root causes of the condition. A new study published in Naunyn-Schmiedeberg's Archives of Pharmacology used cutting-edge scientific methods to dig deeper into the biology of PCOS and identify new targets for treatment.

Researchers combined multiple types of genetic and protein data from large groups of people — including databases from Iceland and the UK — to find specific proteins in the body that appear to play a causal role in PCOS. Think of these proteins as molecular switches that, when malfunctioning, contribute to the disorder. The team identified four top-priority protein targets: FSHB, THOP1, CAMKK1, and PDLIM4. These proteins are involved in hormonal signaling, cellular communication, and inflammation-related pathways.

The scientists also used computer modeling to test whether existing medications might work against these newly identified targets. Some compounds showed promising results, meaning drugs already developed for other conditions might potentially be repurposed to help women with PCOS — a faster and more cost-effective path than developing entirely new medications.

For patients, this research is encouraging because it moves science closer to treatments that target the actual biological causes of PCOS rather than just managing symptoms. It also reinforces the importance of a whole-body approach to hormonal health.

While this research is still in early stages, many women with PCOS are already exploring complementary approaches such as acupuncture to help manage symptoms like irregular cycles, stress, and hormonal imbalance alongside conventional care. If you are interested in exploring acupuncture as part of your PCOS management plan, seek out a licensed and qualified acupuncture practitioner experienced in women's health.

This multi-omics study integrated proteome-wide association studies (PWAS), Mendelian randomization (MR), summary-based MR (SMR), Bayesian colocalization, TWAS, MWAS, and GEO differential expression analysis using large-scale plasma proteomics data from deCODE and UK Biobank cohorts alongside PCOS GWAS summary statistics. From 57 nominally associated candidate proteins, four tier-1 druggable targets were prioritized: FSHB (PPH4 >0.8), and THOP1, CAMKK1, and PDLIM4 (PPH3+PPH4 >0.8), with ERBB4 retained as a secondary candidate. Pathway enrichment implicated lysosomal and MAPK-related mechanisms. Drug prediction via DSigDB and molecular docking identified repurposable compounds including Triciribine and 1,3,5(10)-Estratriene-2,3-diol-17-one, with FSHB demonstrating strong docking affinity at -9.7 kcal/mol. MR-PheWAS suggested limited off-target effects except FSHB-associated reproductive risks. Clinically, these findings advance precision medicine for PCOS and highlight hormonal and inflammatory pathways relevant to acupuncture's proposed mechanisms in regulating HPO axis function and neuroendocrine balance.